MRI offers increasingly reliable visualization of potentially significant prostate cancers, thereby guiding biopsy to allow better sensitivity and negative predictive value. In applying MRI-targeted biopsy, we have learned the significance of MRI findings and evolved pre-biopsy MRI to serve as a means by which to better select patients for biopsy and identify lesions for biopsy. Rather than diagnosing all cancers of the prostate, we have now begun the shift the paradigm to selective identification of only those cancers that may cause harm.
Guest Editors (From top left to bottom right)
Marc A. Bjurlin, DO, MSc
Clinical Assistant Professor of Urology; Director of Urologic Oncology; NYU Lutheran Medical Center, New York, NY, USA; Department of Urology, NYU Langone Medical Center, New York, NY, USA.
Andrew B. Rosenkrantz, MD
Associate Professor of Radiology and Urology; Director of Health Policy; Director of Prostate Imaging, NYU Langone Medical Center, New York, NY, USA.
Herbert Lepor, MD
Professor and Martin Spatz Chairman of Urology, New York University School of Medicine; Urologist in Chief, NYU Langone Medical Center, New York, NY, USA.
Samir S. Taneja, MD
The James M. Neissa and Janet Riha Neissa Professor of Urologic Oncology; Professor of Urology and Radiology; Director, Division of Urologic Oncology, NYU Langone Medical Center, New York, NY, USA.